← Leaderboards
Laura A. Kresty
Ohio State University
$2,875,032
Attributed
$4,176,060
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $422.6K · FY2007–25$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,176,060 · 4
By mechanism
R01$3,522,834 · 2
R21$330,000 · 1
UG3$323,226 · 1
Top collaborators
- Balaraman Kalyanaraman5 shared
- Ming You5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Patrick Lee Green$10,720,230
- Ming You$26,875,453
- Tong Chen$2,428,538
- Amanda Robinson Panfil$689,288
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseIn VivoLinkCell LinePrevention StrategyMalignant NeoplasmsToxic EffectPreventiveIn VitroCell ProliferationUnited StatesMolecularSignal TransductionPre-ClinicalAnimalsProto-Oncogene Proteins C-AktMonitorChemopreventive AgentAutophagocytosisImaging ModalityCarcinogenesisCessation Of LifeCell DeathGrowth
Grant awards (14)
Developing Natural Products to Target IL-8 Signaling and Intercept Progression of Barrettâs Esophagus to Esophageal Adenocarcinoma$323,226
UG3 · FY2025 · CA · contact PI
Chemoprevention of lung cancer by targeting lonidamine to mitochondria$383,989
R01 · FY2023 · CA
Chemoprevention of lung cancer by targeting lonidamine to mitochondria$383,991
R01 · FY2022 · CA
Chemoprevention of lung cancer by targeting lonidamine to mitochondria$422,579
R01 · FY2021 · CA
Chemoprevention of lung cancer by targeting lonidamine to mitochondria$382,111
R01 · FY2020 · CA
Chemoprevention of lung cancer by targeting lonidamine to mitochondria$378,872
R01 · FY2019 · CA
Inhibition of Reflux-Induced Esophageal Adenocarcinoma by Proanthocyanidins$235,190
R01 · FY2016 · CA · contact PI
Inhibition of Reflux-Induced Esophageal Adenocarcinoma by Proanthocyanidins$82,285
R01 · FY2016 · CA · contact PI
Inhibition of Reflux-Induced Esophageal Adenocarcinoma by Proanthocyanidins$317,475
R01 · FY2015 · CA · contact PI
Inhibition of Reflux-Induced Esophageal Adenocarcinoma by Proanthocyanidins$307,951
R01 · FY2014 · CA · contact PI
Inhibition of Reflux-Induced Esophageal Adenocarcinoma by Proanthocyanidins$310,916
R01 · FY2013 · CA · contact PI
Inhibition of Reflux-Induced Esophageal Adenocarcinoma by Proanthocyanidins$317,475
R01 · FY2012 · CA · contact PI
Targeting Histone Deacetylation: A Tool for Chemopevention of Esophageal Cancer$150,000
R21 · FY2008 · CA · contact PI
Targeting Histone Deacetylation: A Tool for Chemopevention of Esophageal Cancer$180,000
R21 · FY2007 · CA · contact PI